State Street
ZVRA icon

State Street’s Zevra Therapeutics ZVRA Stock Holding History

State Street’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.1M Buy
1,681,999
+120,430
+8% +$1.34M ﹤0.01% 2259
2026
Q1 		$14.6M Buy
1,561,569
+78,613
+5% +$709K ﹤0.01% 2409
2025
Q4 		$13.3M Buy
1,482,956
+55,665
+4% +$526K ﹤0.01% 2484
2025
Q3 		$13.6M Buy
1,427,291
+185,633
+15% +$1.86M ﹤0.01% 2451
2025
Q2 		$10.9M Buy
1,241,658
+65,110
+6% +$528K ﹤0.01% 2544
2025
Q1 		$8.81M Buy
1,176,548
+3,992
+0.3% +$31.7K ﹤0.01% 2610
2024
Q4 		$9.78M Buy
1,172,556
+399,731
+52% +$3.41M ﹤0.01% 2641
2024
Q3 		$5.36M Buy
772,825
+52,966
+7% +$360K ﹤0.01% 2936
2024
Q2 		$3.53M Buy
719,859
+36,687
+5% +$174K ﹤0.01% 3079
2024
Q1 		$3.96M Buy
683,172
+47,112
+7% +$290K ﹤0.01% 3017
2023
Q4 		$4.17M Buy
636,060
+7,833
+1% +$36.6K ﹤0.01% 3035
2023
Q3 		$3.03M Buy
628,227
+33,814
+6% +$169K ﹤0.01% 3152
2023
Q2 		$3.03M Buy
594,413
+484,373
+440% +$2.61M ﹤0.01% 3224
2023
Q1 		$605K Buy
110,040
+7,400
+7% +$39.1K ﹤0.01% 3675
2022
Q4 		$471K Hold
102,640
– – ﹤0.01% 3788
2022
Q3 		$640K Hold
102,640
– – ﹤0.01% 3690
2022
Q2 		$458K Sell
102,640
-448,975
-81% -$2.05M ﹤0.01% 3860
2022
Q1 		$2.77M Buy
551,615
+12,798
+2% +$81.4K ﹤0.01% 3444
2021
Q4 		$4.69M Sell
538,817
-7,732
-1% -$69K ﹤0.01% 3272
2021
Q3 		$5.1M Buy
546,549
+52,741
+11% +$532K ﹤0.01% 3230
2021
Q2 		$6.33M Buy
+493,808
New +$5.31M ﹤0.01% 3131

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street's ZVRA Position: Q2 2026 in Review

State Street increased its Zevra Therapeutics (ZVRA) stake by 7.7% in Q2 2026, buying an estimated $1.34M and bringing the position to 1,681,999 shares worth $24.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2259.

State Street first reported a position in ZVRA in Q2 2021 and has held it in 21 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • State Street held 1,681,999 shares of Zevra Therapeutics worth $24.1M as of Q2 2026.
  • State Street bought 120,430 Zevra Therapeutics shares in Q2 2026, an estimated $1.34M.
  • Zevra Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2259 holding.
  • State Street first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.